September 1, 2017 Gormley’s Take: Writing War on Cancer’s Next Chapter –– Biotech startups seek to widen benefits of revolutionary cell-therapy treatments WSJ Pro Venture Capital features MPM’s Chris Bardon and TCR2 Read full article